A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB)

References

• American Academy of Pediatrics. Red Book: 2015 report of the committee on infectious diseases.
   Google Scholar
• Villena R, Safadi MAP, Valenzuela MT, et al. Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines. Hum Vaccin Immunother. 2018;14(5):1042–1057. DOI:10.1080/21645515.2018.1458175
   PubMed Web of Science ®Google Scholar
• Wang B, Santoreneos R, Giles L, et al. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37(21):2768–2782. DOI:10.1016/j.vaccine.2019.04.020.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Meningococcal vaccines: WHO position paper - November 2011. Wkly Epidemiol Rec. 2011;86(47):521–539.
   PubMedGoogle Scholar
• Shen J, Begum N, Ruiz-Garcia Y, et al. Range of invasive meningococcal disease sequelae and health economic application - a systematic and clinical review. BMC Public Health. 2022;22(1):1078. DOI:10.1186/s12889-022-13342-2
   PubMed Web of Science ®Google Scholar
• Viner RM, Booy R, Johnson H, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11(9):774–783. DOI:10.1016/S1474-4422(12)70180-1
   PubMed Web of Science ®Google Scholar
• Borrow R, Alarcon P, Carlos J, et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16(4):313–328. DOI:10.1080/14760584.2017.1258308
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Menigococcal disease: surveillance. Disease trends 2010-2019. 2022. [cited 2023 May 5]. Available from: https://www.cdc.gov/meningococcal/surveillance/
   Google Scholar
• European Centre for Disease Prevention and Control. Invasive meningococcal disease. In: ECDC. Annual epidemiological report for 2018. Stockholm: ECDC; 2022.
   Google Scholar
• Gandhi A, Balmer P, York LJ. Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba(R)). Postgrad Med. 2016;128(6):548–556. DOI:10.1080/00325481.2016.1203238
   PubMed Web of Science ®Google Scholar
• Serruto D, Bottomley MJ, Ram S, et al. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine. 2012;30(Suppl 2):B87–B97. DOI:10.1016/j.vaccine.2012.01.033
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A. 2006;103(29):10834–10839. DOI:10.1073/pnas.0603940103
   PubMed Web of Science ®Google Scholar
• GSK. Bexsero Summary of Product Characteristics. 2020. [cited 2023 May 5]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/bexsero
   Google Scholar
• GSK. Bexsero Prescribing Information. 2020. [cited 2023 May 5]. Available from: https://www.fda.gov/media/90996/download
   Google Scholar
• Australian product information - trumenba (Meningococcal group B vaccine) suspension for injection pre-filled syringe. 2019. [cited 2023 May 5] Available from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2017-PI-02674-1&d=20211026172310101
   Google Scholar
• Pfizer. Trumenba (Meningococcal group B vaccine) Prescribing Information. [cited 2023 May 5] Avilable from: https://www.fda.gov/media/89936/download.
   Google Scholar
• Pfizer. Trumenba Summary of Product Characteristics. [cited 2023 May 5] Available from: https://www.ema.europa.eu/en/documents/product-information/trumenba-epar-product-information_en.pdf
   Google Scholar
• Pfizer. Trumenba product monograph. [cited 2023 May 5] Available from: https://www.pfizer.ca/files/Trumenba_PM_EN.pdf
   Google Scholar
• Vaccine Scheduler ECDC. Meningococcal disease: recommended vaccinations. [cited 2023 May 5]. Available from: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=48&SelectedCountryIdByDisease=-1
   Google Scholar
• de Santé HA. Stratégie de vaccination pour la prévention des infections invasives à méningocoques : Le sérogroupe B et la place de BEXSERO®[Vaccination strategy for the prevention of invasive meningococcal infections: Serogroup B and the place of Bexsero]. [cited 2023 May 5]. Available from: https://www.has-sante.fr/jcms/p_3066921/fr/strategie-de-vaccination-pour-la-prevention-des-infections-invasives-a-meningocoques-le-serogroupe-b-et-la-place-de-bexser
   Google Scholar
• UK Health Security Agency. Complete routine immunisation schedule. [cited 2023 May 5] Available from: https://www.gov.uk/government/publications/the-complete-routine-immunisation-schedule/the-complete-routine-immunisation-schedule-from-february-2022
   Google Scholar
• Azzari C, Moriondo M, Nieddu F, et al. Effectiveness and impact of the 4CMenB vaccine against group b meningococcal disease in two italian regions using different vaccination schedules: a five-year retrospective observational study (2014–2018). Vaccines (Basel). 2020;8(3):469. DOI:10.3390/vaccines8030469
   PubMed Web of Science ®Google Scholar
• Deceuninck G, Lefebvre B, Tsang R, et al. Impact of a mass vaccination campaign against serogroup b meningococcal disease in the saguenay-lac-saint-jean region of quebec four years after its launch. Vaccine. 2019;37(31):4243–4245. DOI:10.1016/j.vaccine.2019.06.021
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Andrews N, Parikh SR, et al. Vaccination of infants with meningococcal Group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309–317. DOI:10.1056/NEJMoa1901229
   PubMed Web of Science ®Google Scholar
• Martinon-Torres F, Banzhoff A, Azzari C, et al. Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination. J Infect. 2021;83(1):17–26. DOI:10.1016/j.jinf.2021.04.031
   PubMed Web of Science ®Google Scholar
• McMillan M, Wang B, Koehler AP, et al. Impact of meningococcal B vaccine on invasive meningococcal disease in adolescents. Clin Infect Dis. 2021;73(1):e233–e237. DOI:10.1093/cid/ciaa1636
   PubMed Web of Science ®Google Scholar
• Parikh SR, Andrews NJ, Beebeejaun K, et al. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388(10061):2775–2782. DOI:10.1016/S0140-6736(16)31921-3
   PubMed Web of Science ®Google Scholar
• Chiu NC, Huang LM, Willemsen A, et al. Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: a phase 3, open-label, randomized study. Hum Vaccin Immunother. 2018;14(5):1075–1083. DOI:10.1080/21645515.2018.1425659
   PubMed Web of Science ®Google Scholar
• Findlow J, Bai X, Findlow H, et al. Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers. Vaccine. 2015;33(29):3322–3330. DOI:10.1016/j.vaccine.2015.05.027
   PubMed Web of Science ®Google Scholar
• Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307(6):573–582. DOI:10.1001/jama.2012.85
   PubMed Web of Science ®Google Scholar
• Kimura A, Toneatto D, Kleinschmidt A, et al. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol. 2011;18(3):483–486. DOI:10.1128/CVI.00304-10
   PubMed Web of Science ®Google Scholar
• Macias Parra M, Gentile A, Vazquez Narvaez JA, et al. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: a phase 3b, randomized controlled trial. Vaccine. 2018;36(50):7609–7617. DOI:10.1016/j.vaccine.2018.10.096
   PubMed Web of Science ®Google Scholar
• Prymula R, Esposito S, Zuccotti GV, et al. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I). Hum Vaccin Immunother. 2014;10(7):1993–2004. DOI:10.4161/hv.28666
   PubMed Web of Science ®Google Scholar
• Santolaya ME, O’Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012;379(9816):617–624. DOI:10.1016/S0140-6736(11)61713-3
   PubMed Web of Science ®Google Scholar
• Snape MD, Saroey P, John TM, et al. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. CMAJ. 2013;185(15):E715–724. DOI:10.1503/cmaj.130257
   PubMed Web of Science ®Google Scholar
• Toneatto D, Ismaili S, Ypma E, et al. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccin. 2011;7(6):646–653. DOI:10.4161/hv.7.6.15482
   PubMed Web of Science ®Google Scholar
• Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381(9869):825–835. DOI:10.1016/S0140-6736(12)61961-8
   PubMed Web of Science ®Google Scholar
• Sheerin D, O’Connor D, Dold C, et al. Comparative transcriptomics between species attributes reactogenicity pathways induced by the capsular group B meningococcal vaccine, 4CMenB, to the membrane-bound endotoxin of its outer membrane vesicle component. Sci Rep. 2019;9(1):13797. DOI:10.1038/s41598-019-50310-0
   PubMedGoogle Scholar
• Zafack JG, Bureau A, Skowronski DM, et al. Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials. BMJ Open. 2019;9(5):e026953. DOI:10.1136/bmjopen-2018-026953
   PubMed Web of Science ®Google Scholar
• Martinon-Torres F, Carmona Martinez A, Simko R, et al. Antibody persistence and booster responses 24-36 months after different 4CMenB vaccination schedules in infants and children: a randomised trial. J Infect. 2018;76(3):258–269. DOI:10.1016/j.jinf.2017.12.005
   PubMed Web of Science ®Google Scholar
• Flacco ME, Manzoli L, Rosso A, et al. Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis. Lancet Infect Dis. 2018;18(4):461–472. DOI:10.1016/S1473-3099(18)30048-3
   PubMed Web of Science ®Google Scholar
• Isitt C, Cosgrove CA, Ramsay ME, et al. Success of 4CMenB in preventing meningococcal disease: evidence from real-world experience. Arch Dis Child. 2020;105(8):784–790. DOI:10.1136/archdischild-2019-318047
   PubMed Web of Science ®Google Scholar
• Jorch G, Tapiainen T, Bonhoeffer J, et al. Unexplained sudden death, including sudden infant death syndrome (SIDS), in the first and second years of life: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25(31):5707–5716. DOI:10.1016/j.vaccine.2007.02.068
   PubMed Web of Science ®Google Scholar
• Beran J, Drazan D, Enweonye I, et al. Immunogenicity and safety of investigational MenABCWY vaccine and of 4CMenB and MenACWY vaccines administered concomitantly or alone: a phase 2 randomized study of adolescents and young adults. mSphere. 2021;6(6):e0055321. DOI:10.1128/mSphere.00553-21
   PubMed Web of Science ®Google Scholar
• Marshall HS, Koehler AP, Wang B, et al. Safety of meningococcal B vaccine (4CMenB) in adolescents in Australia. Vaccine. 2020;38(37):5914–5922. DOI:10.1016/j.vaccine.2020.07.009
   PubMed Web of Science ®Google Scholar
• Bryan P, Seabroke S, Wong J, et al. Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study. Lancet Child Adolesc Health. 2018;2(6):395–403. DOI:10.1016/S2352-4642(18)30103-2
   PubMedGoogle Scholar
• Hall GC, Douglas I, Heath PT, et al. Post-licensure observational safety study after meningococcal B vaccine 4CMenB (Bexsero) vaccination within the routine UK immunisation program. Vaccine. 2021;39(24):3296–3303. DOI:10.1016/j.vaccine.2021.02.065
   PubMed Web of Science ®Google Scholar
• De Serres G, Billard MN, Gariepy MC, et al. Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada. Vaccine. 2018;36(52):8039–8046. DOI:10.1016/j.vaccine.2018.10.095
   PubMed Web of Science ®Google Scholar
• Mentzer D, Oberle D, Keller-Stanislawski B. Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016. Euro Surveill. 2018;23(17):17–00468. doi:10.2807/1560-7917.ES.2018.23.17.17-00468
   PubMedGoogle Scholar
• Thabuis A, Tararbit K, Taha MK, et al. Community outbreak of serogroup B invasive meningococcal disease in Beaujolais, France, February to June 2016: from alert to targeted vaccination. Euro Surveill. 2018;23(28):1700590. DOI:10.2807/1560-7917.ES.2018.23.28.1700590
   PubMedGoogle Scholar
• McNamara LA, Shumate AM, Johnsen P, et al. First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak. Pediatrics. 2015;135(5):798–804. DOI:10.1542/peds.2014-4015
   PubMed Web of Science ®Google Scholar
• Perez-Vilar S, Dores GM, Marquez PL, et al. Safety surveillance of meningococcal group B vaccine (Bexsero(r)), vaccine adverse event reporting system, 2015-2018. Vaccine. 2022;40(2):247–254. DOI:10.1016/j.vaccine.2021.11.071
   PubMed Web of Science ®Google Scholar
• Stefanizzi P, Bianchi FP, Spinelli G, et al. Postmarketing surveillance of adverse events following meningococcal B vaccination: data from Apulia Region, 2014-19. Hum Vaccin Immunother. 2022;18(1):1–6. DOI:10.1080/21645515.2021.2011652
   Web of Science ®Google Scholar
• Fernandez-Prada M, Martinez-Ortega C, Hidalgo-Pena L, et al. Adverse reactions associated with meningococcal group B vaccine (4CMenB) in adults in special situations. Farm Hosp. 2018;42(5):191–196. DOI:10.7399/fh.10989
   PubMed Web of Science ®Google Scholar
• Harcourt S, Morbey RA, Bates C, et al. Estimating primary care attendance rates for fever in infants after meningococcal B vaccination in England using national syndromic surveillance data. Vaccine. 2018;36(4):565–571. DOI:10.1016/j.vaccine.2017.11.076
   PubMed Web of Science ®Google Scholar
• Dubus M, Ladhani S, Vasu V. Prophylactic paracetamol after meningococcal B vaccination reduces postvaccination fever and septic screens in hospitalized preterm infants. Pediatr Infect Dis J. 2020;39(1):78–80. DOI:10.1097/INF.0000000000002507
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Mukherjee D, Rajai A, et al. MenB (Bexsero) immunisation side effects in extremely premature infants (<28 weeks). Arch Dis Child Fetal Neonatal Ed. 2018;103(1):F85. DOI:10.1136/archdischild-2017-314009
   PubMed Web of Science ®Google Scholar
• Kapur S, Bourke T, Maney JA, et al. Emergency department attendance following 4-component meningococcal B vaccination in infants. Arch Dis Child. 2017;102(10):899–902. DOI:10.1136/archdischild-2016-311020
   PubMed Web of Science ®Google Scholar
• Murdoch H, Wallace L, Bishop J, et al. Risk of hospitalisation with fever following MenB vaccination: self-controlled case series analysis. Arch Dis Child. 2017;102(10):894–898. DOI:10.1136/archdischild-2017-313079
   PubMed Web of Science ®Google Scholar
• Nainani V, Galal U, Buttery J, et al. An increase in accident and emergency presentations for adverse events following immunisation after introduction of the group B meningococcal vaccine: an observational study. Arch Dis Child. 2017;102(10):958–962. DOI:10.1136/archdischild-2017-312941
   Web of Science ®Google Scholar
• Stowe J, Andrews NJ, Turner PJ, et al. The risk of Kawasaki disease after pneumococcal conjugate & meningococcal B vaccine in England: a self-controlled case-series analysis. Vaccine. 2020;38(32):4935–4939. DOI:10.1016/j.vaccine.2020.05.089
   PubMed Web of Science ®Google Scholar
• De Serres G, Billard MN, Gariepy MC, et al. Nephrotic syndrome following four-component meningococcal B vaccination: epidemiologic investigation of a surveillance signal. Vaccine. 2019;37(35):4996–5002. DOI:10.1016/j.vaccine.2019.07.017
   PubMed Web of Science ®Google Scholar
• Andrews N, Stowe J, Miller E. Nephrotic syndrome in infants and toddlers before and after introduction of the meningococcal B vaccine programme in England: an ecological study. Vaccine. 2020;38(31):4816–4819. DOI:10.1016/j.vaccine.2020.05.055
   PubMed Web of Science ®Google Scholar
• Sharkey K, Beernink PT, Langley JM, et al. Anti-factor H antibody reactivity in young adults vaccinated with a meningococcal serogroup B vaccine containing factor H binding protein. mSphere. 2019;4(4). DOI:10.1128/mSphere.00393-19
   PubMed Web of Science ®Google Scholar
• Nicolosi L, Rizzo C, Gattinara GC, et al. Safety and tolerability of Meningococcus B vaccine in patients with chronical medical conditions (CMC). Ital J Pediatr. 2019;45(1):133. DOI:10.1186/s13052-019-0730-y
   PubMed Web of Science ®Google Scholar
• van den Broek B, van Els C, Kuipers B, et al. Multi-component meningococcal serogroup B (MenB)-4C vaccine induces effective opsonophagocytic killing in children with a complement deficiency. Clin Exp Immunol. 2019;198(3):381–389. DOI:10.1111/cei.13368
   PubMed Web of Science ®Google Scholar
• Bonhoeffer J, Kohl K, Chen R, et al. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine. 2002;21(3–4):298–302. DOI:10.1016/S0264-410X(02)00449-8
   PubMed Web of Science ®Google Scholar
• Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis and kawasaki disease, council on cardiovascular disease in the young, American heart association. Circulation. 2004;110(17):2747–2771. DOI:10.1161/01.CIR.0000145143.19711.78
   PubMed Web of Science ®Google Scholar
• Bonhoeffer J, Menkes J, Gold MS, et al. Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine. 2004;22(5–6):557–562. DOI:10.1016/j.vaccine.2003.09.008
   PubMed Web of Science ®Google Scholar
• NICE. Guideline NG143. Fever in under 5s: assessment and initial management. [cited 2023 May 5] Available from: https://www.nice.org.uk/guidance/ng143/chapter/Recommendations#clinical-assessment-of-children-with-fever.
   Google Scholar
• Robinson JL. Canadian Paediatric Society Infectious Diseases Immunization Committee. Immunization for meningococcal serogroup B: what does the practitioner need to know? Paediatr Child Health. 2014;19(2):91–98. DOI:10.1093/pch/19.2.91.
   PubMed Web of Science ®Google Scholar
• UK NHS. Using paracetamol to prevent and treat fever after MenB vaccination. [cited 2023 May 5] Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/717281/PHE_paracetamol-menB-A4-2018_01.pdf
   Google Scholar
• National Immunisation Office. Immunisation Meningococcal B. [cited 2023 May 5] Available from: https://www.hse.ie/eng/health/immunisation/hcpinfo/othervaccines/meningococcalb/#Paracetamol%20after%20MenB%20vaccine
   Google Scholar
• Gabinete do Secretário de Estado da Saúde. Aprova o novo esquema vacinal do Programa Nacional de Vacinação (PNV), revo-gando, com exceção do seu n.º 6, o Despacho n.º 10441/2016, de 9 de agosto (2019) [Approves the new vaccination scheme of the National Vaccination Program (PNV), revo-gando, with the exception of its paragraph 6, Order No. 10441/2016, of August 9 (2019)]. [cited 2023 May 5]. Available from: https://dre.pt/application/conteudo/127608823
   Google Scholar
• Marshall HS, Chen G, Clarke M, et al. Adolescent, parent and societal preferences and willingness to pay for meningococcal B vaccine: a discrete choice experiment. Vaccine. 2016;34(5):671–677. DOI:10.1016/j.vaccine.2015.11.075
   PubMed Web of Science ®Google Scholar